|Bid||148.08 x 1000|
|Ask||148.24 x 900|
|Day's range||147.30 - 151.25|
|52-week range||115.03 - 217.25|
|Beta (5Y monthly)||1.70|
|PE ratio (TTM)||7.33|
|Earnings date||02 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||226.64|
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Shares of biotech Novavax (NASDAQ: NVAX) have plunged 91% in the past year as the company has struggled to make its mark in the coronavirus vaccine market. Novavax's lack of success in this space is even more troubling, considering global COVID-19 vaccine sales will drop substantially starting this year, so even the leaders in the field have struggled of late. While it seems highly unlikely that Novavax will soar by that much anytime soon, perhaps the broader question is whether there's a substantial upside ahead for the company.
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the Government of the Republic of Kenya have finalized an agreement to establish an mRNA manufacturing facility in the Republic of Kenya.